Skip to main content



660W Redwood St, Howard Hall 596 Baltimore, MD 21201-1541

Phone (Primary):


Phone (Secondary):




Download CV

Education and Training

Ph.D. - Molecular Cell Biology and Hematology, 2005, Kagoshima University, Kagoshima, Japan

Postdoctoral Fellowship - Vascular Biology, 2006, Johns Hopkins University, Baltimore, MD


Professional Experience

2006–2012  Research Associate, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD

2012–2019  Assistant Professor, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD



Dr. Kazuyo Kegan is an Assistant Professor of Anesthesiology Department at University of Maryland School of Medicine. She earned her undergraduate and Ph.D. degrees from Kagoshima University in Japan and completed her postdoctoral research training at Johns Hopkins University. The goal of Dr. Kegan’s research program is to understand the mechanisms, regulation, and functional outcomes of immune responses in the pulmonary vasculature during the development of pulmonary hypertension. She has strong expertise in vascular biology and has focused on the role of inflammatory mediators in pulmonary angiogenesis, vasculogenesis, and remodeling, particularly under hypoxic conditions.

She is a member of the American Heart Association, the American Thoracic Society and the Pulmonary Hypertension Association. She has been recognized with the Young Investigator Award, and the 2011 - 2013 Pfizer Research Fellowships in Pulmonary Arterial Hypertension, the 2016-2017 PHA Proof of Concept Research Grant from the Pulmonary Hypertension Association of the American Thoracic Society.

Research/Clinical Keywords

Vascular biology, pulmonary hypertension, vascular inflammation, endothelial injury, macrophage biology, immune response, pulmonary angiogenesis, vasculogenesis, and remodeling.

Highlighted Publications

  1. Johns RA, Takimoto E, Meuchel LW, Elsaigh E, Zhang A, Heller NM, Semenza GL, Yamaji-Kegan K*. Hypoxia-inducible factor 1α is a critical downstream mediator for hypoxia-induced mitogenic factor (FIZZ1/RELMα)-induced pulmonary hypertension. Arterio Thromb Vasc Biol. 36(1):134-144, 2016. PMID: 26586659. 
  2. Dasgupta P, Dorsey NJ, Li J, Qi X, Smith EP, Yamaji-Kegan K, Keegan AD. The adaptor protein insulin receptor substrate 2 inhibits alternative macrophage activation and allergic lung inflammation. Sci Signal. 9(433):ra63, 2016. PMID: 27330190

  3. Yamaji-Kegan K*, Takimoto E, Zhang A, Weiner NC, Meuchel LW, Berger AE, Cheadle C, Johns RA. Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 306(12):L1090-L1103, 2014. PMID: 24793164. *Corresponding author.

  4. Yamaji-Kegan K, Su Q, Angelini DJ, Myers AC, Cheadle C, Johns RA. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4–dependent mechanism. J Immunol 185(9):5539-5548, 2010. PMID: 20889544

  5. Yamaji-Kegan K, Su Q, Angelini DJ, Johns RA. IL-4 is proangiogenic in the lung under hypoxic conditions. J Immunol 182(9):5469-5476, 2009. PMID: 19380795

  6. Yamaji-Kegan K, Su Q, Angelini DJ, Champion HC, Johns RA. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. Am J Physiol Lung Cell Mol Physiol 291(6): L1159-L1168, 2006. PMID: 16891392

Research Interests

Dr. Kegan is currently working to determine the mechanisms by which vascular injury and the subsequent immune response by macrophages contribute to disease progression in pulmonary hypertension using in vivo pathophysiology, in vitro cellular and molecular biology, and genetic and biochemical approaches. Clinical samples from patients with pulmonary hypertension also are utilized to uncover the relevant signaling pathways that might reveal new therapeutic targets. She is principal investigator of an NIH-funded research program with the ultimate goal of identifying new therapeutic targets to treat pulmonary hypertension.

In the News




Professional Activity

American Heart Association (AHA)
American Thoracic Society (ATS)
Pulmonary Hypertension Association (PHA)
North American Vascular Biology Organization (NAVBO)
Pulmonary Vascular Research Institute (PVRI)

Links of Interest



Edit Icon - Click to update your profileUpdate Your Profile